References
- Ali S, Saleh H, Sethi S, Sarkar FH, Philip PA. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br. J. Cancer 107(8), 1354–1360 (2012).
- Jiao LR, Frampton AE, Jacob J et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS ONE 7(2), e32068 (2012).
- Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem. Cell Biol. 42(8), 1348–1354 (2010).
- Shigoka M, Tsuchida A, Matsudo T et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol. Int. 60(5), 351–357 (2010).
- Wu CW, Ng SS, Dong YJ et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61(5), 739–745 (2012).
- Lee EJ, Gusev Y, Jiang J et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120(5), 1046–1054 (2007).
- Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest. Endosc. 75(2), 319–331 (2012).
- Xu K, Zhou L, Liang B et al. Safety and accuracy of percutaneous core needle biopsy in examining pancreatic neoplasms. Pancreas 41(4), 649–651 (2012).
- Panarelli NC, Chen YT, Zhou XK, Kitabayashi N, Yantiss RK. MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas 41(5), 685–690 (2012).
- Munding JB, Adai AT, Maghnouj A et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int. J. Cancer 131(2), 86–95 (2012).
- Szafranska AE, Doleshal M, Edmunds HS et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin. Chem. 54(10), 1716–1724 (2008).
- Preis M, Gardner TB, Gordon SR et al. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 17(17), 5812–5821 (2011).
- Hanoun N, Delpu Y, Suriawinata AA et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin. Chem. 56(7), 1107–1118 (2010).
- Torrisani J, Bournet B, du Rieu MC et al. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum. Gene Ther. 20(8), 831–844 (2009).
- Sadakari Y, Ohtsuka T, Ohuchida K et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP 11(6), 587–592 (2010).
- Matthaei H, Wylie D, Lloyd MB et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin. Cancer Res. 18(17), 4713–4724 (2012).
- Ryu JK, Matthaei H, Dal Molin M et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology 11(3), 343–350 (2011).
- Habbe N, Koorstra JB, Mendell JT et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther. 8(4), 340–346 (2009).
- Frampton AE, Krell J, Jacob J, Stebbing J, Jiao LR, Castellano L. microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma. Expert Rev. Anticancer Ther. 11(12), 1837–1842 (2011).
- Frampton AE, Krell J, Zhang Y, Stebbing J, Castellano L, Jiao LR. The role of miR-10b in metastatic pancreatic ductal adenocarcinoma. Surgery 152(5), 936–938 (2012).
- Frampton AE, Pai M, Krell J, Vlavianos P, Jiao LR, Spalding DR. The ‘malignant truth’ about the recurrence of pancreatic intraductal papillary mucinous neoplasms. Arch. Surg. 147(10), 977–980 (2012).
Website
- Ingenuity Systems. www.ingenuity.com